Has Felton Anderson, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,321,592 in general payments to Felton Anderson, MD across 900 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Felton Anderson, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Felton Anderson, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Felton Anderson, MD

Cardiovascular Disease · Washington, DCNPI 1588655914

Payments from drug & device makers

$2,321,592in general payments, 2019–2025

Across 900 payments — averaging $2579.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$1.9M
Eli Lilly$343K
Pfizer$76K
AstraZeneca$3K
Bayer$2K
Amgen$1K
plus $10K from 44 others

$150,466in research payments, 2019–2025

Across 14 payments — averaging $10,748 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$149K
Regeneron$2K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	127	$1,886,959
Eli Lilly	20	$343,417
Pfizer	73	$75,633
AstraZeneca	107	$2,594
Bayer	46	$1,910
Amgen(2 entities)	60	$1,050
Boston Scientific	15	$1,045
Lilly USA, LLC	52	$1,013
GSK	54	$926
Abbott	19	$881
Merck	62	$870
Boehringer Ingelheim	42	$817
Novo Nordisk	39	$654
E.r. Squibb & Sons, L.L.C.	26	$535
Gilead	34	$432
Scpharmaceuticals Inc.	14	$374
Sanofi-aventis U.S. LLC	20	$339
Esperion Therapeutics, Inc.	12	$299
Medtronic	2	$198
Bioprotect Medical, Inc.	1	$136
Atricure, Inc.	4	$134
Johnson & Johnson	6	$118
Corcept Therapeutics	4	$117
Lexicon Pharmaceuticals, Inc.	3	$89
Smith+Nephew	5	$87
Teva Pharmaceuticals USA, Inc.	5	$85
Biohaven Pharmaceutical Holding Company Ltd.	4	$78
Regeneron Healthcare Solutions, Inc.	3	$74
Eisai Inc.	3	$61
Ironwood Pharmaceuticals, Inc	4	$60
Actelion Pharmaceuticals US, Inc.	3	$58
Philips North America LLC	3	$57
Arbor Pharmaceuticals, Inc.	4	$56
Kaleo, Inc.	3	$52
Idorsia Pharmaceuticals US Inc	2	$42
Verona Pharma, Inc.	2	$41
Azurity Pharmaceuticals, Inc.	2	$33
Takeda Pharmaceuticals U.S.A., Inc.	2	$30
Mannkind Corporation	1	$30
Hikma Pharmaceuticals USA	2	$26
Zealand Pharma US, Inc.	1	$25
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	1	$24
Heartflow, Inc.	1	$24
Avanir Pharmaceuticals, Inc.	1	$20
Edwards Lifesciences	1	$17
USWM, LLC	1	$16
Bridgebio Pharma, Inc.	1	$16
G Medical Diagnostic Services, Inc.	1	$15
Amarin Pharma, Inc.	1	$13
Eyevance Pharmaceuticals LLC	1	$13

How this compares

$2,321,592 in reported general payments places this provider in the 95th percentile of 105 cardiovascular disease providers in District of Columbia.

See all cardiovascular disease providers in District of Columbia →

Medicare billing

Part B allowed, 2024

$449,648

Medicare patients

573

Services billed

4,050

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Washington

Neil WeissmanWashington$1.9M
Mardi Gomberg-MaitlandWashington$1.1M
Hayder HashimWashington$989K
Joshua YamamotoWashington$376K
Jaffar KhanWashington$330K
Susan O'DonoghueWashington$207K
Richard KatzWashington$207K
Isaac Opoku-AsareWashington$146K
Zuyue WangWashington$143K
Andrew ChoiWashington$127K

See the full list for District of Columbia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →